Skip to main content
SpringerLink
Log in

Acne and Rosacea

  • Chapter
  • First Online:
Dermatoanthropology of Ethnic Skin and Hair

Abstract

Acne vulgaris is the most common dermatologic disorder among patients with skin of color. Rosacea, although less common among ethnic populations, is not rare and often goes unrecognized in skin of color. The pathogenesis of these conditions in ethnic populations is similar to that of Caucasians, although there are unique differences, such as the tendency to develop dyschromias, hypertrophic scarring, and keloid formation in the former group. While acne and rosacea are seen in both Caucasian and non-Caucasian populations, variations in the clinical appearances in ethnic populations can present diagnostic and therapeutic challenges. Early initiation of treatment for these inflammatory conditions is paramount because delays or misdiagnosis may lead to common sequelae such as post-inflammatory hypo- or hyperpigmentation. In this chapter, we will expand upon the important differences and highlight areas that deserve special attention in the diagnosis and treatment of acne and rosacea in patients with skin of color.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol. 2012;11:466–73.

    PubMed  Google Scholar 

  2. Lawson C, Hollinger J, Sethi S, Rodney I, Sarkar R, Dlova N, Callender V. Updates in the understanding and treatments of skin & hair disorders in women of color. Int J Womens Dermatol. 2015;1(2):59–75.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Perkins AC, Cheng CE, Hillebrand GG, Miyamoto K, Kimball AB. Comparison of the epidemiology of acne vulgaris among Caucasians, Asian, Continental Indian and African American women. J Eur Acad Dermatol Venerol. 2011;25:1054–60.

    Google Scholar 

  4. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80:387–94.

    PubMed  Google Scholar 

  5. Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney JA. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32:388–90.

    CAS  PubMed  Google Scholar 

  6. Taylor SC, Cook-Bolden F, Rahman Z, Strachan D. Acne vulgaris in skin of color. J Am Acad Dermatol. 2002;46(suppl 2):S98–106.

    Article  PubMed  Google Scholar 

  7. Warrier AG, Kligman AM, Harper RA, Bowman J, Wickett RR. A comparison of black and white skin using non-invasive methods. J Soc Cosmet Chem. 1996;47:229–40.

    Google Scholar 

  8. Nicolaides N, Rothman S. Studies on the chemical composition of human hair fat. II, The overall composition with regard to age, sex and race. J Invest Dermatol. 1952;21:90.

    Google Scholar 

  9. Kligman AM, Shelley WB. An investigation of the biology of the sebaceous gland. J Invest Dermatol. 1958;30:99–125.

    Article  CAS  PubMed  Google Scholar 

  10. Kircik N. Advances in the understanding of the pathogenesis of inflammatory acne. J Drugs Dermatol. 2016;15(1 Suppl 1):s7–10.

    CAS  PubMed  Google Scholar 

  11. Halder RM, Holmes YC, Bridgeman-Shah S, Kligman AM. A clinicohistopathologic study of acne vulgaris in black females. J Invest Dermatol. 1996;106:888.

    Google Scholar 

  12. Halder RM, Brooks HL, Callender VD. Acne in ethnic skin. Dermatol Clin. 2003;21(4):609–15, vii.

    Google Scholar 

  13. Callender VD. Acne in ethnic skin: special considerations for therapy. Dermatol Ther. 2004;17:184–95.

    Article  PubMed  Google Scholar 

  14. Callender VD, Alexis AF, Daniels SR, Kawata AK, Burk CT, Wilcox TK, Taylor SC. Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne. J Clin Aesthet Dermatol. 2014;7(7):19–31.

    PubMed  PubMed Central  Google Scholar 

  15. Rendon MI, Rodriguez DA, Kawata AK, Degboe AN, Wilcox TK, Burk CT, Daniels SR, Roberts WE. Acne treatment patterns, expectations, and satisfaction among adult females of different races/ethnicities. Clin Cosmet Investig Dermatol. 2015;2(8):231–8.

    Google Scholar 

  16. Taylor S, Badreshia-Bansal S, Callender V, Gathers R, Rodriguez D. Treatments for skin of color. Edinburgh: Saunders; 2011.

    Google Scholar 

  17. Spann CT. Ten tips for treating acne vulgaris in Fitzpatrick skin types IV-VI. J Drugs Dermatol. 2011;10(6):654–7.

    PubMed  Google Scholar 

  18. Shah SK, Alexis AF. Acne in skin of color: practical approaches to treatment. J Dermatol Treat. 2010;21:206–11.

    Article  Google Scholar 

  19. Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. J Clin Aesthet Dermatol. 2010;3:24–38.

    PubMed  PubMed Central  Google Scholar 

  20. Wolf JE Jr. Potential anti-inflammatory effects of topical retinoids and retinoid analogues. Adv Ther. 2002;19(3):109–18.

    Google Scholar 

  21. Ortonne JP, Passeron T. Melanin pigmentary disorders: treatment update. Dermatol Clin. 2005;23(2):209–26.

    Article  PubMed  Google Scholar 

  22. Halder RM. The role of retinoids in the management of cutaneous conditions in blacks. J Am Acad Dermatol. 1998;39(2 Pt 3):S98–103.

    Article  CAS  PubMed  Google Scholar 

  23. Geria AN, Lawson CN, Halder RM. Topical retinoids for pigmented skin. J Drugs Dermatol. 2011;10(5):483–9.

    CAS  PubMed  Google Scholar 

  24. Zeichner J. Strategies to minimize irritation and potential iatrogenic post-inflammatory pigmentation when treating acne patients with skin of color. J Drugs Dermatol. 2011;10(12 Suppl):s25–6.

    PubMed  Google Scholar 

  25. Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25(10):664–7.

    Article  PubMed  Google Scholar 

  26. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes. Cutis. 2001;67(2 Suppl):21–4.

    CAS  PubMed  Google Scholar 

  27. Vargas-Diez E, Hofmann MA, Bravo B, Malgazhdarova G, Katkhanova OA, Yutskovskaya Y. Azelaic acid in the treatment of acne in adult females: case reports. Skin Pharmacol Physiol. 2014;27(Suppl 1):18–25.

    Article  PubMed  Google Scholar 

  28. Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C, Garrett S; United States/Canada Dapsone Gel Study Group. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56:439.e1–10.

    Google Scholar 

  29. Fellner C. Pharmaceutical approval update. P T. 2016;41(4):220–1.

    Google Scholar 

  30. Kircik LH. Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. J Drugs Dermatol. 2010;9:1407–11.

    PubMed  Google Scholar 

  31. Mouton RW, Jordaan HF, Schneider JW. A new type of minocycline-induced cutaneous hyperpigmentation. Clin Exp Dermatol. 2004;29:8–14.

    Article  CAS  PubMed  Google Scholar 

  32. Soung J, Cohen J, Phelps R, Cohen S. Case reports: minocycline-induced hyperpigmentation resolves during oral isotretinoin therapy. J Drugs Dermatol. 2007;6:1232–6.

    PubMed  Google Scholar 

  33. Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med. 1999;159(5):493–7.

    Article  CAS  PubMed  Google Scholar 

  34. Muller P, Dubreil P, Mahé A, Lamaury I, Salzer B, Deloumeaux J, Strobel M. Drug hypersensitivity syndrome in a West-Indian population. Eur J Dermatol. 2003;13(5):478–81.

    Google Scholar 

  35. Zeichner JA. Evaluating and treating the adult female patient with acne. J Drugs Dermatol. 2013;12:1418–27.

    CAS  Google Scholar 

  36. Alexis AF. Acne vulgaris in skin of color: understanding nuances and optimizing treatment outcomes. J Drugs Dermatol. 2014;13(6):s61–5.

    PubMed  Google Scholar 

  37. Kelly AP, Sampson DD. Recalcitrant nodulocystic acne in black Americans: treatment with isotretinoin. J Natl Med Assoc. 1987;79:1266–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Ghaffarpour G, Mazloomi S, Soltani-Arabshahi R, Seyed KS. Oral isotretinoin for acne, adjusting treatment according to patient’s response. J Drugs Dermatol. 2006;5(9):878–82.

    PubMed  Google Scholar 

  39. Ng PP, Goh CL. Treatment outcome of acne vulgaris with oral isotretinoin in 89 patients. Int J Dermatol. 1999;38(3):213–6.

    Article  CAS  PubMed  Google Scholar 

  40. Dhir R, Gehi NP, Agarwal R, More YE. Oral isotretinoin is as effective as a combination of oral isotretinoin and topical anti-acne agents in nodulocystic acne. Indian J Dermatol Venereol Leprol. 2008;74(2):187.

    Article  PubMed  Google Scholar 

  41. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol. 2001;2(4):213–7.

    Article  CAS  PubMed  Google Scholar 

  42. Woolery-Lloyd HC, Keri J, Doig S. Retinoids and azelaic acid to treat acne and hyperpigmentation in skin of color. J Drugs Dermatol. 2013;12(4):434–7.

    CAS  PubMed  Google Scholar 

  43. Karnik J, Baumann L, Bruce S, Callender V, Cohen S, Grimes P, Joseph J, Shamban A, Spencer J, Teldaldi R, Werschler W, Smith S. A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. J Am Acad Dermatol. 2014;71:77–83.

    Article  CAS  PubMed  Google Scholar 

  44. Cohen BE, Elbuluk N. Microneedling in skin of color: a review of uses and efficacy. J Am Acad Dermatol. 2016;74(2):348–55.

    Article  PubMed  Google Scholar 

  45. Jacyk WK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis. 2001;68(4 Suppl):48–54.

    Google Scholar 

  46. Tu P, Li GQ, Zhu XJ, et al. A comparison of adapalene gel 0.1% vs. tretinoin gel 0.025% in the treatment of acne vulgaris in China. J Eur Acad Dermatol Venereol. 2001;15(Suppl 3):31–6.

    Article  PubMed  Google Scholar 

  47. Goh CL, Tang MB, Briantais P, Kaoukhov A, Soto P. Adapalene gel 0.1% is better tolerated than tretinoin gel 0.025% among healthy volunteers of various ethnic origins. J Dermatolog Treat. 2009;20(5):282–8.

    Article  PubMed  Google Scholar 

  48. Tirado-Sanchez A, Espindola YS, Ponce-Olivera RM, Bonifaz A. Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single-center, randomized, double-blinded, placebo-controlled clinical trial on Mexican patients (skin type III-IV). J Cosmet Dermatol. 2013;12:103–7.

    Article  PubMed  Google Scholar 

  49. Grimes PE, Callender VD. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77:45–50.

    PubMed  Google Scholar 

  50. Alexis AF, Johnson LA, Kerrouche N, Callender VD. A subgroup analysis to evaluate the efficacy and safety of adapalene-benzoyl peroxide topical gel in black subjects with moderate acne. J Drugs Dermatol. 2014;13:170–4.

    CAS  PubMed  Google Scholar 

  51. Callender VD. Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel: efficacy & tolerability of treatment in moderate to severe acne. J Drugs Dermatol. 2012;11:643–8.

    CAS  PubMed  Google Scholar 

  52. Callender VD, Young CM, Kindred C, Taylor SC. Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne-induced post-inflammatory hyperpigmentation in patients with skin of color. J Clin Aesthet Dermatol. 2012;5:25–32.

    Google Scholar 

  53. Kircik LH. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. J Drugs Dermatol. 2011;10:586–90.

    CAS  PubMed  Google Scholar 

  54. Piette WW, Taylor S, Pariser D, Jarratt M, Sheth P, Wilson D. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. Arch Dermatol. 2008;144:1564–70.

    Article  CAS  PubMed  Google Scholar 

  55. Alexis AF, Burgess C, Callender VD, Herzog JL, Roberts WE, Schweiger ES, Stockton TC, Gallagher CJ. The efficacy and safety of topical dapsone gel, 5% for the treatment of acne vulgaris in adult females with skin of color. J Drugs Dermatol. 2016;15(2):197–204.

    CAS  PubMed  Google Scholar 

  56. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S; Differin Study Group. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005;4(3):138–46.

    Google Scholar 

  57. Fleischer AB Jr, Dinehart S, Stough D, Plott RT; Solodyn Phase 2 Study Group; Solodyn Phase 3 Study Group. Safety and efficacy of a new extended-release formulation of minocycline. Cutis. 2006;78:21–31.

    Google Scholar 

  58. Ullah G, Noor SM, Bhatti Z, Ahmad M, Bangash AR. Comparison of oral azithromycin with oral doxycycline in the treatment of acne vulgaris. Br J Dermatol. 2014;171:1508–16.

    Article  Google Scholar 

  59. Tan J, Humphrey S, Vender R, Barankin B, Gooderham M, Kerrouche N, Audibert F, Lynde C; POWER study group. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol. 2014;171:1508–16.

    Google Scholar 

  60. Fabbrocini G, De Vita V, Monfrecola A, De Padova MP, Brazzini B, Teixeira F, Chu A. Percutaneous collagen induction: an effective and safe treatment for post-acne scarring in different skin phototypes. J Dermatolog Treat. 2014;25(2):147–52.

    Article  CAS  PubMed  Google Scholar 

  61. Alexis AF, Coley MK, Nijhawan RI, Luke JD, Shah SK, Argobi YA, Nodzenski M, Veledar E, Alam M. Nonablative fractional laser resurfacing for acne scarring in patients with Fitzpatrick skin phototypes IV–VI. Dermatol Surg. 2016;42(3):392–402.

    Article  CAS  PubMed  Google Scholar 

  62. Alexis AF. Rosacea in patients with skin of color: uncommon but not rare. Cutis. 2010;86(2):60–2.

    PubMed  Google Scholar 

  63. Al-Dabagh A, Davis SA, McMichael AJ, Feldman SR. Rosacea in skin of color: not a rare diagnosis. Dermatol Online J. 2014;20(10).

    Google Scholar 

  64. Jayawant SS, Feldman SR, Camacho FT, Yentzer B, Balkrishnan R. Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea. J Dermatolog Treat. 2008;19(5):267–73.

    Article  PubMed  Google Scholar 

  65. Coda AB, Hata T, Miller J, Audish D, Kotol P, Two A, Shafiq F, Yamasaki K, Harper JC, Del Rosso JQ, Gallo RL. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69(4):570–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Bae YI, Yun SJ, Lee JB, Kim SJ, Won YH, Lee SC. Clinical evaluation of 168 Korean patients with rosacea: the sun exposure correlates with the erythematotelangiectatic subtype. Ann Dermatol. 2009;21(3):243–9.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Culp B, Scheinfeld N. Rosacea: a review. P T. 2009;34(1):38–45.

    PubMed  PubMed Central  Google Scholar 

  68. Khoo CT, Saad MN. Rhinophyma in a negro: case report. Br J Plast Surg. 1980;33(2):161–3.

    Article  CAS  PubMed  Google Scholar 

  69. Furukawa M, Kanetou K, Hamada T. Rhinophyma in Japan. Int J Dermatol. 1994;33(1):35–7.

    Article  CAS  PubMed  Google Scholar 

  70. Al Balbeesi AO, Halawani MR. Unusual features of rosacea in saudi females with dark skin. Ochsner J. 2014;14(3):321–7.

    Google Scholar 

  71. Rosen T, Stone MS. Acne rosacea in blacks. J Am Acad Dermatol. 1987;17(1):70–3.

    Article  CAS  PubMed  Google Scholar 

  72. Browning DJ, Rosenwasser G, Lugo M. Ocular rosacea in blacks. Am J Ophthalmol. 1986;101(4):441–4.

    Article  CAS  PubMed  Google Scholar 

  73. Williams HC, Ashworth J, Pembroke AC, Breathnach SM. FACE–facial Afro-Caribbean childhood eruption. Clin Exp Dermatol. 1990;15(3):163–6.

    Article  CAS  PubMed  Google Scholar 

  74. Child FJ, Fuller LC, Higgins EM, Du Vivier AW. A study of the spectrum of skin disease occurring in a black population in south-east London. Br J Dermatol. 1999;141(3):512–7.

    Article  CAS  PubMed  Google Scholar 

  75. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4):499–512; quiz 513–4.

    Google Scholar 

  76. Nielsen PG. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br J Dermatol. 1983;108(3):327–32.

    Article  CAS  PubMed  Google Scholar 

  77. Wolf JE Jr. The role of topical metronidazole in the treatment of rosacea. Cutis. 2004;73(1 Suppl):19–28.

    PubMed  Google Scholar 

  78. Del Rosso JQ, Kircik LH. Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid. J Drugs Dermatol. 2014;13(12):s101–7.

    PubMed  Google Scholar 

  79. Del Rosso JQ, Baum EW, Draelos ZD, Elewski BE, Fleischer AB Jr, Kakita LS, Thiboutot D. Azelaic acid gel 15%: clinical versatility in the treatment of rosacea. Cutis. 2006;78(5 Suppl):6–19.

    PubMed  Google Scholar 

  80. Deeks ED. Ivermectin: a review in Rosacea. Am J Clin Dermatol. 2015;16(5):447–52.

    Article  PubMed  Google Scholar 

  81. Sibenge S, Gawkrodger DJ. Rosacea: a study of clinical patterns, blood flow, and the role of Demodex folliculorum. J Am Acad Dermatol. 1992;26(4):590–3.

    Article  CAS  PubMed  Google Scholar 

  82. Scheinfeld N. 1% Ivermectin cream (Soolantra) for the treatment of Rosacea. Skinmed. 2015;13(3):222–4.

    Google Scholar 

  83. Johnson AW, Johnson SM. The role of topical brimonidine tartrate gel as a novel therapeutic option for persistent facial erythema associated with Rosacea. Dermatol Ther (Heidelb). 2015;5(3):171–81.

    Article  Google Scholar 

  84. Jackson JM, Knuckles M, Minni JP, Johnson SM, Belasco KT. The role of brimonidine tartrate gel in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2015;23(8):529–38.

    Article  Google Scholar 

  85. Routt ET, Levitt JO. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. J Am Acad Dermatol. 2014;70(2):e37–8.

    Article  PubMed  Google Scholar 

  86. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44:995–8.

    Article  CAS  PubMed  Google Scholar 

  87. Fujiwara S, Okubo Y, Irisawa R, Tsuboi R. Rosaceiform dermatitis associated with topical tacrolimus treatment. J Am Acad Dermatol. 2010;62(6):1050–2.

    Article  PubMed  Google Scholar 

  88. El-Heis S, Buckley DA. Rosacea-like eruption due to topical pimecrolimus. Dermatol Online J. 2015;18;21(5).

    Google Scholar 

  89. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular Rosacea: results of a randomized trial. Arch Dermatol. 2003;139(11):1444–50.

    Article  CAS  PubMed  Google Scholar 

  90. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(4 Suppl):3–11.

    PubMed  Google Scholar 

  91. Colón LE, Johnson LA, Gottschalk RW. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis. 2007;79(4):317–21.

    PubMed  Google Scholar 

  92. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular Rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836–45.

    Article  PubMed  Google Scholar 

  93. Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Liu H, Jacovella J. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular Rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316–23.

    PubMed  Google Scholar 

  94. Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M on behalf of the Brimonidine Phase II Study Group. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012; 166(3):633–641.

    Google Scholar 

  95. Holmes AD, Waite KA, Chen MC, Palaniswamy K, Wiser TH, Draelos ZD, Rafal ES, Werschler WP, Harvey AE. Dermatological adverse events associated with topical brimonidine gel 0.33% in subjects with erythema of Rosacea: a retrospective review of clinical studies. J Clin Aesthet Dermatol. 2015;8(8):29–35.

    Google Scholar 

  96. Lee DH, Li K, Suh DH. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. Br J Dermatol. 2008;158(5):1069–76.

    Article  CAS  PubMed  Google Scholar 

  97. Del Rosso JQ, Webster GF, Jackson M, Rendon M, Rich P, Torok H, Bradshaw M. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of Rosacea. J Am Acad Dermatol. 2007;56(5):791–802.

    Article  PubMed  Google Scholar 

  98. Alexis AF, Webster G, Preston NJ, Caveney SW, Gottschalk RW. Effectiveness and safety of once-daily doxycycline capsules as monotherapy in patients with Rosacea: an analysis by Fitzpatrick skin type. J Drugs Dermatol. 2012;11(10):1219–22.

    CAS  PubMed  Google Scholar 

  99. Sanchez J, Somolinos AL, Almodóvar PI, Webster G, Bradshaw M, Powala C. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of Rosacea. J Am Acad Dermatol. 2005;53(5):791–7.

    Google Scholar 

  100. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8(7):639–48.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatology Associates of Lancaster, 1650 Crooked Oak Drive, Suite 200, Lancaster, PA, 17601, USA

    Christina N. Lawson

  2. Callender Dermatology and Cosmetic Center, 12200 Annapolis Rd, Suite 315, Glenn Dale, MD, 20769, USA

    Valerie D. Callender

Authors
  1. Christina N. Lawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valerie D. Callender
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina N. Lawson .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Center for Ethnic Skin, Boston University, Boston, Massachusetts, USA

    Neelam A. Vashi

  2. University of California, San Francisco, San Francisco, California, USA

    Howard I. Maibach

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Lawson, C.N., Callender, V.D. (2017). Acne and Rosacea. In: Vashi, N., Maibach, H. (eds) Dermatoanthropology of Ethnic Skin and Hair. Springer, Cham. https://doi.org/10.1007/978-3-319-53961-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-53961-4_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-53960-7

  • Online ISBN: 978-3-319-53961-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation